Factors suggesting inherited cancer syndrome.
According to the latest knowledge, hereditary kidney cancers may account for 5–8% of all kidney cancers, and it may be more common than previously thought. Hereditary RCC is often characterized by an early age of onset (approximately 45 years), typical histological pattern, and frequently the bilaterality and multicentricity of the primary tumor. Wilms’ tumor (nephroblastoma) is the most common kidney tumor of childhood. More than 15 syndromes with inherited susceptibility to kidney cancer are known, and there are over 25 known genes associated with them. Most of these are dominantly inherited in which the offspring of the proband has a 50% chance of inheriting a gene mutation with susceptibility to kidney cancer. The aggressiveness of hereditary RCCs and recommended surgery varies depending on the syndrome and mutation type. Also, systemic therapy may be optional. Multigene next generation sequencing (NGS) panel technology allows genes of interest to be studied quickly and cost-effectively. Sequencing investigations have improved the accuracy of hereditary cancer diagnoses. Diagnostic utility has been hugely increased by multigene NGS panels. It is important to identify hereditary cancer susceptibility, because the risk of cancer in the mutation carriers can be reduced. In this review article, the latest literature on syndromes subjecting to hereditary kidney cancer and recommended follow-up is summarized.
- von Hippel-Lindau
- hereditary papillary RCC
- hereditary leiomyomatosis and RCC
- Wilms’ tumor
- hereditary kidney cancer syndromes
- genetic susceptibility
Kidney cancer is the 16th most common cancer worldwide with over 400,000 cases in 2018 representing approximately 2.2% of all diagnosed malignancies worldwide . The majority of primary renal malignancies are renal cell carcinomas (RCCs) with most of the remaining comprising upper tract urothelial carcinoma (UTUC). The mean age of onset of RCC is approximately 60–70 years. The most common kidney tumor of childhood is Wilms’ tumor (nephroblastoma). In the European Union, the estimated annual number of new kidney cancers is approximately 46,000 . Etiologic risk factors for kidney cancer development are male sex, obesity, and tobacco, in addition to hypertension [3, 4, 5], acquired cystic kidney disease , and inherited susceptibility. Prognostic factors of different protein and gene expressions in RCC have been studied [7, 8].
According to the latest knowledge, hereditary kidney cancers may account for 5–8% of all kidney cancers , and it may be more common than previously thought . In those RCC patients without clear cell RCC (ccRCC) subtype, the amount of germline high-risk mutations is greater, 12% . Susceptibility to kidney cancer may be caused by high-risk, moderate-risk, or low-risk gene mutation . Even the carriership of high-risk gene mutation does not always lead to kidney cancer. The risk for kidney cancer (penetrance) varies in different syndromes. In some cases, the predisposed genetic factor to kidney cancer is chromosomal aberration, for example, as in constitutional chromosomal 3 translocation with 6 or 8 of family (Table 2). In hereditary cancer, the impact of environmental factors is small.
More than 15 syndromes with inherited susceptibility to kidney cancer are known, and there are over 25 known genes associated with them. Most of these are dominantly inherited in which the offspring of the proband has a 50% chance of inheriting a gene mutation with susceptibility to kidney cancer.
2. Identifying hereditary kidney cancer
Hereditary kidney cancer syndrome is often characterized by an early age of onset (approximately 45 years) , typical histological pattern, and frequently the bilaterality and multicentricity of the primary tumor (Table 1). By evaluating the family history of diagnosed cancer cases, benign tumors, and diagnostic gene test results, it is possible to identify families with hereditary kidney cancer (Tables 2 and 3).
|Multiple close relatives with benign or malign tumors of the syndrome|
|Atypically young age of onset for tumors of the syndrome|
|Relative with two tumors of the syndrome (two examples below)|
|Typical histological finding (e.g., rare subtype or multiplicity) or clinical picture|
|von Hippel-Lindau (VHL)||Hereditary papillary RCC (HPRC)||Hereditary leiomyomatosis and RCC (HLRCC)||Birt-Hogg-Dubé (BHD)||Constitutional chromosomal 3 translocation|
|RCC subtype||Clear cell carcinoma||Papillary type 1||Papillary type 2, collecting duct||Most often chromophobe ± oncocytoma||Clear cell carcinoma|
|Risk for RCC||40%||Nearly 100%||20–30%||30%||30%|
|Typical age of onset for RCC||40 years||50–70 years||Less than 40 years||50 years|
|Biology of RCC||Bilaterality, multiple tumors||Bilaterality, multiple tumors, microscopic lesions as much as 1000||Unilaterality, solitarity, aggressive, highly potential to metastasize||Bilaterality, multiple tumors||Bilaterality, multiple tumors|
|Typical surgery||Minimal invasive||Minimal invasive or radical nephrectomy||Radical nephrectomy||Minimal invasive|
|Other signs of the syndrome than RCC||Retinal hemangioma/CNS hemangioblastoma, pheochromocytoma||None||Uterine leiomyomas in almost every patient, uterine leiomyosarcoma, cutaneous leiomyomas||Cutaneous hair follicle benign tumors and pulmonary cysts in almost every patient||Thyroid, bladder, pancreatic and gastric cancer|
|Reference||[13, 14]||[15, 16]||[17, 18, 19, 20]||[21, 22]|||
|Lynch syndrome||Cowden syndrome||Hyperparathyroid jaw tumor syndrome||Hereditary pheochromocytoma and paraganglioma||Li-Fraumeni syndrome||BAP1 tumor predisposition syndrome|
|Kidney cancer subtype||Upper tract urothelial carcinoma||Clear cell, papillary, chromophobe||Papillary type 1 RCC, adult Wilms’ tumor||Clear cell RCC, chromophobe RCC, oncocytoma||RCC and Wilms’ tumor||Clear cell RCC|
|Risk for kidney cancer||Multiple||15%||Uncommon||10%||Low||10%|
|Other signs of the syndrome than RCC||Bowel cancer, uterine, ovarian cancer||Mucocutaneous papules, hamartomas, macrocephaly, thyroid cancer, uterine cancer, intestinal polyps||Ossifying jaw fibromas, renal cysts, parathyroid adenoma/carcinoma, uterine tumors||Paragangliomas, pheochromocytoma, GIST||Brain tumor, sarcoma, leukemia and other cancer types||Uveal and cutaneous melanoma, mesothelioma|
It is possible that there exists only a single hereditary cancer syndrome case in the family due to de novo mutations (autosomal dominant) which means that the person’s parents do not have the same mutation. There are hot spot regions in genes where mutation can easier develop during meiosis of germ cells. In addition to this, the risk of hereditary kidney cancer is linked to some congenital multisystem syndromes, such as Beckwith-Wiedemann syndrome and tuberous sclerosis (Table 4). When such a multisystemic syndrome is detected, appropriate follow-up care is provided as with hereditary kidney cancer families.
|Tuberous sclerosis||Beckwith-Wiedemann syndrome||Perlman syndrome|
|Kidney cancer subtype||Clear cell, papillary, chromophobe||Wilms’ tumor||Wilms’ tumor|
|Risk for kidney cancer||Less than 5%||Around 5%||30–60%|
|Typical age of onset for kidney cancer||35 years||Primarily in the first 8 years of life||Neonatally|
|Inheritance||Autosomal dominant||Autosomal dominant, sporadic||Autosomal recessive|
|Other signs of the syndrome than kidney cancer||Renal angiomyolipomas, hypopigmentation, seizures, learning difficulties, angiofibromas, shagreen patches, oral mucosal lesions, subependymal giant cell astrocytoma||Neonatal hypoglycemia, macrosomia, macroglossia, hemihyperplasia, omphalocele, renal abnormalities||Fetal ascites, macrosomia, visceromegaly, generalized hypotonia|
It is suspected that hereditary kidney cancer is underdiagnosed. Identifying the families with increased risk for kidney cancer allows clinicians to improve the prognosis of persons with genetic cancer susceptibility. This review discussed the characteristics of inherited kidney cancer and how to improve their prognosis (Table 5).
|The aim is to improve the early detection of cancer|
|Occurrence can be prevented by removing the precursors identified in the monitoring|
|Occurrence can be prevented by surgical procedures|
|Sometimes genetic information can guide the choice of medication|
3. Basic cancer genetics
In hereditary and sporadic cancer, the normal genome regulation is impaired , and cancer susceptibility is caused by both inherited germline gene mutations and somatic gene mutations in tissue that occurred over time. However, in sporadic cases the inherited gene mutations cause low risk for kidney cancer . Of all clear cell-type RCCs (sporadic or hereditary), 75% have a somatic mutation in the von Hippel-Lindau tumor suppressor gene (VHL) in the short arm of chromosome . According to Vogelstein’s research group, chance has a major impact in the development of cancer-causing mutations during DNA replication in normal, noncancerous stem cells . Current understanding is that about four to seven mutations in key driver genes is sufficient to cause cancer to develop .
Genes associated with cancer predisposition are oncogenes or tumor suppressor genes. Oncogenes act as gain of function. Mutation in the other allele is sufficient to produce the altered protein. An example of this is the
Caretaker genes are responsible for genomic stability by detecting damage to the genome, such as single- or double-stranded DNA breaks . Disruption in these genes leads to genomic instability: an increase in the number of spontaneous mutations that cause new mutations in oncogenes and growth restriction genes. Mutations in the caretaker genes are responsible for a number of cancer susceptibility syndromes. For example, germline mutation in the growth restriction gene
Genetics of cancer is only partially known. Advanced technological methods can detect previously unknown mutations in germline and tumors. Knowledge of the biology of hereditary cancer also increases the understanding of sporadic cancers, as the same disease genes are found in hereditary and non-hereditary cancers: e.g., mutated
4. Genetic counseling and supporting families with hereditary cancer
It is important to identify hereditary cancer susceptibility, because the risk of cancer, morbidity, and mortality in the mutation carriers can be reduced both in cancer patients and healthy relatives in the family. If the family mutation is known, healthy family members with mutation can participate in preventive studies. If the person does not have the known family mutation, there is no need to have follow-up care because the risk of the cancer is the same as for an average population.
Diagnostic gene testing on cancer patients is carried out in the clinical genetic units, but diagnostic genetic testing can also be ordered by a treating oncologist or surgeon for patients with kidney cancer. There are established principles for considering genetic testing in the case of suspected hereditary cancer susceptibility (Table 6) . If there is a genetic test that is appropriate for the situation, the American Society of Clinical Oncology (ASCO) recommends access to genetic testing. Before testing the individuals, informed consent should be requested after adequate information and counseling . For genetic testing the patient’s peripheral blood, lymphocyte DNA is examined for identifying a possible hereditary mutation.
|Hereditary cancer is suspected|
|The result of the gene test should be adequately interpreted|
|Gene testing has one of the following benefits:|
The investigation for finding the family mutation is always started with the affected person. A medical geneticist will determine who could have mutation with increased kidney cancer risk in the family. If there are no surviving cancer patients in the family, with the permission of the relative, from the pathology department, a sample of the deceased person may be requested to have healthy tissue DNA for genetic examination.
The result of the genetic testing gives information about the cancer risk of relatives. Healthy at-risk relatives should have access to genetic counseling and predictive genetic testing after counseling if they decide (Council of Europe’s The Convention on Human Rights and Biomedicine in Article 12, 1997). The clinical genetics units offer this service. The geneticist will have the opportunity to provide the laboratory with reliable information about the family mutation and arrange for the laboratory the DNA sample of the family’s index patient, which is a control sample, positive control, to obtain a reliable test result. Counseling before predictive genetic testing is nondirective and includes insight of the patient and the family. In counseling, the patient and family receive not only information but also support. Increased anxiety or distress has been documented in both counselors and their families around testing when investigating hereditary VHL susceptibility . The Genetic Information Nondiscrimination Act of the Council of Europe’s Convention in Article 11, in 1997, was passed to prevent forms of genetic discrimination by employment and health insurance. The Council of Europe’s Convention prohibits the transfer of genetic information to employers in order to prevent employment discrimination. Insurance discrimination is discussed in counseling. In Finland, genetic testing is organized by public health care, which is why very few gene tests are conducted privately.
Participation in predictive genetic testing has been studied in the Finnish Lynch syndrome families, which are at high risk for colorectal cancer and endometrial carcinoma in the uterus. Approximately 80% of the members of the family participated in genetic counseling, and 95% of them performed genetic prediction . The main reasons for participating in predictive genetic testing are the potential for cancer detection in surveillance monitoring, improved treatment options in many Lynch syndrome cancer types, and improved cancer prognosis.
After the genetic testing, the counselor should always receive an interpretation of the significance of the genetic test result [43, 44]. Different mutations in the same disease gene, for example, in the inherited VHL gene, can have varying effects on cancer risk and prognosis . The genetic practitioner will assess the significance of the result for each family separately. It is useful to wait until the age of 18 to allow an offspring to reach an age of consent in those inherited syndromes in which the age of onset is in adulthood. However, the early age of onset in condition like VHL could have devastating complications without early detection and management, and therefore in this syndrome predictive testing is recommended to at-risk children in family.
5. Genotype-phenotype correlation in kidney cancer
6. The diagnostic impact of gene testing evolution
Multigene next generation sequencing (NGS) panel technology allows genes of interest to be studied quickly and cost-effectively. By focused massive parallel sequencing, it is possible to examine those exons of the genome’s genes that are of interest in diagnosing the cause of inherited kidney cancer. The method can also investigate boundaries between exons and introns. A gene panel for hereditary kidney cancer covers approximately 25 genes and can be ordered from different companies. Clinical picture may sometimes indicate a mutation in particular gene or genes, which can be separately examined. However, often hereditary mutation may be in many different genes according to patient and family history, and then multigene panel-based NGS will be more economical than Sanger or NGS sequencing of several different genes. Sequencing results are obtained in about 4 weeks. The gene content of the panels is regularly updated by laboratories as information on genes associated with kidney cancer is published continuously. A limitation of parallel sequencing is that they cannot recognize large intrinsic deletions or duplicates, and for this another method is required that investigates exome CNVs. A majority of hereditary mutations are located in the exome region. The whole genome NGS is not yet a routine method, but it is used in scientific studies. By the NGS method, the diagnostic utility of hereditary cancers has been hugely improved.
Information on the clinical significance associated with mutations is reviewed in registers (e.g., InSiGHT and ClinVar) . With the development of research techniques, more variants of uncertain significance (VUS) are now observed. Currently, these are also variants of which it is unknown whether they are benign or pathogenic and explain the patient’s predisposition to cancer. In some situations, the variant may be classified as likely pathogenic. Prediction programs can be used to evaluate a variant’s ability to cause disease (in silico analysis) [49, 50]. For example, the ExAC database can be used to check the prevalence of the variant in the population. As techniques evolve, it is increasingly possible to study the functional change in RNA structure caused by VUS alteration, which would be relevant to the quality of the resulting protein. In order to clarify the nature of the uncertain variants, the geneticist may arrange the so-called segregation analysis in family . Finding the same hereditary variant from several relatives with cancer would strengthen the conclusion that the variant explains the cases in the family. Information is being collected internationally as laboratories collect VUS they observe into databases and doctors publish case reports. However, in already well-known genes such as BRCA and Lynch syndrome genes, VUS alterations are relatively rarely detected.
During counseling, the geneticist will inform what is known about the significance of the identified variant. If the significance of the variant remains open, the geneticist and laboratory experts may reclassify the change after few years. The increased use of multigene NGS panels in patient work expands the knowledge on the different pathogenic variants in the human DNA. The number of VUS changes will therefore decrease in the next few years . It is important that counseling provides reliable information on the examination results and therefore VUS modifications are not used as a basis for prophylactic surgery or to determine the risk of relatives’ cancer.
7. Treatment in hereditary kidney cancer
For several RCC syndromes, studies have found that conservative management appears to preserve renal function without increased mortality. In certain syndromes, such as HLRCC, early and aggressive treatment may be preferable [17, 20]. Each subtype of RCC may need to be treated differently by systemic therapy, but no phase III clinical trial data exist from distinct treatments [51, 52]. The prognosis was inferior for papillary metastatic RCC (mRCC) compared to clear cell mRCC when patients were treated with the same evidence-based treatment in a study by Staehler . The understanding of the metabolic and epigenetic abnormalities underlying the symptoms of hereditary kidney cancer-associated genes may lead to the development of novel diagnostic biomarkers and novel treatment modalities for kidney cancer .
8. Surveillance in hereditary kidney cancer families
Recommendations for follow-up care should correspond to the level of risk associated with the genetic variant tested . The aim of the monitoring is to improve the early detection of cancer in families with hereditary renal cancer. Monitoring recommendations includes regular kidney imaging: the healthy carrier of a gene mutation predisposing to kidney cancer will usually undergo abdominal MRI scans on a regular basis (Table 7). The frequency of follow-up depends on the biological nature of the family syndrome. Several monitoring planes have been proposed for hereditary kidney cancer syndromes, for example, by Freifeld  and Carlo . Also, PDQ Cancer Information Summaries  has a suggestion for surveillance in certain syndromes predisposing to hereditary renal cancer.
|von Hippel-Lindau (VHL)||Hereditary papillary RCC (HPRC)||Hereditary leiomyomatosis and RCC (HLRCC)||Birt-Hogg-Dubé (BHD)|
|RCC subtype||Clear cell carcinoma||Papillary type 1||Papillary type 2, collecting duct||Most often chromophobe ± oncocytoma|
|Risk for RCC||40%||Nearly 100%||20–30%||30%|
|Typical age of onset for RCC||40 years||50–70 years||Less than 40 years||50 years|
|Abdominal magnetic imaging||Annually starting at the age of 10||Annually starting at the age of 30||Annually starting at the age of 5–20 years||Annually starting at the age of 20 years|
|Other surveillance||Biannual brain and spine MRI starting at the age of 11|
Ophthalmological and audiological exam
Plasma-free metanephrines/urinary metanephrines
|None||Dermatological and gynecological exam||Dermatological exam and CT of the chest|
Tracking intervals may be less frequent, for example, for HPRC, and more frequent for others, such as HLRCC in the case of an early onset of 10 years  and several reported cases among children. However, the estimated risk of developing RCC before age 20 is estimated to be only around 1–2%, whereas the lifetime risk of RCC among
In Lynch syndrome, which is a high risk for upper tract ureotelic carcinoma, the risk of colorectal cancer can be reduced by removing intestinal adenomas at regular checkups, which results in the same mortality to colorectal cancer in the carriers of Lynch gene mutation as in the general population.
9. Future perspectives
The contents of routine gene panels are based on the knowledge on kidney cancer susceptibility genes. If a patient’s DNA sequencing has failed to identify the hereditary mutation, RNA sequencing may identify the specific diagnosis . If there are three patients in the family, trio exome analysis may be a pivotal method. Potentially, tumor tissue-only test would be a useful method to find out novel kidney cancer susceptibility genes and mutations in kidney cancer patients, as the knowledge on hereditary kidney cancer genes is still limited. This investigation is not available currently.
Tumor tissue-only gene tests by next generation sequencing with targeted genes may be soon routinely used for cancer patients’ pharmacogenetic genotyping and analyzing their tumor tissue’s somatic mutations to tailor their medical treatment . The same method could be also a first step analysis for identifying the hereditary cancer mutation in a gene that is known in literature as a susceptibility gene. An additional test of patient’s peripheral lymphocyte should then be used to confirm the susceptive mutation as hereditary mutation.
The growing knowledge on the biology of hereditary kidney cancer produces information about driver genes in kidney cancer tumorigenesis and may develop diagnostics and therapeutic methods for kidney cancer in general . Knowledge on evidence-based medicine in metastatic hereditary kidney cancer  is under active study. Analysis of induced pluripotent stem cells (iPSC) from HPRC pointed that drug screening and precision medicine are possible for hereditary kidney cancer . Preventive medicine may be achieved for healthy persons with familial mutation predisposing to kidney cancer .
Prospective studies about the method of follow-up in healthy persons with family kidney cancer susceptibility mutation are warranted. The optimal onset to start follow-up in
Knowledge on the clinical significance of mutations helps to improve prognosis in families with hereditary cancer. Understanding of hereditary kidney cancer syndromes on their molecular basis improves the utility of specific diagnosis . In the future, increased knowledge of cancer genetics is likely to enable the development of targeted drug therapies. Today, hereditary mutations are detected by DNA testing of white blood cell lymphocytes. Tumor tissue-only tests to identify the hereditary kidney cancer are not yet available.
Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018; 68(6):394-426
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019; 144(8):1941-1953
Bergström A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. International Journal of Cancer. 2001; 91:421-430. Erratum in: International Journal of Cancer. 2001; 92:927
Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. The New England Journal of Medicine. 2000; 343:1305-1311
Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. International Journal of Cancer. 2005; 114(1):101-108
Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clinical Journal of the American Society of Nephrology. 2007; 2(4):750-756
Kankuri-Tammilehto MK, Söderström KO, Pelliniemi TT, et al. Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Research. 2010; 30(7):3023-3030
Rabjerg M. Identification and validation of novel prognostic markers in renal cell carcinoma. Danish Medical Journal. 2017; 64(10):B5339
Ball MW, Shuch BM. Inherited kidney cancer syndromes. Current Opinion in Urology. 2019; 29(4):334-343
Carlo MI, Hakimi AA, Stewart GD, et al. Familial kidney cancer: Implications of new syndromes and molecular insights. European Urology. 2019; 76(6):754-764
Carlo MI, Mukherjee S, Mandelker D, et al. Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma. JAMA Oncology. 2018; 4(9):1228-1235
Foulkes WD. Inherited susceptibility to common cancers. The New England Journal of Medicine. 2008; 359:2143-2153
McNeill A, Rattenberry E, Barber R, Killick P, et al. Genotype-phenotype correlations in VHL exon deletions. American Journal of Medical Genetics. Part A. 2009; 149A(10):2147-2151
Zbar B, Kaelin W, Maher E, Richard S. Third international meeting on von Hippel-Lindau disease. Cancer Research. 1999; 59(9):2251-2253
Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics. 1997; 16(1):68-73
Schmidt LS, Nickerson ML, Angeloni D, et al. Early onset hereditary papillary renal carcinoma: Germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. The Journal of Urology. 2004; 172(4 Pt 1):1256-1261
Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. Journal of Medical Genetics. 2006; 43:523-526
Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. American Journal of Human Genetics. 2003; 73:95-106
Vahteristo P, Koski TA, Näätsaari L, et al. No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. Familial Cancer. 2010; 9(2):245-251
Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittomäki K, Tomlinson I, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): Renal cancer risk, surveillance and treatment. Familial Cancer. 2014; 13(4):637-644
Furuya M, Yao M, Tanaka R, et al. Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birt-Hogg-Dube syndrome. Clinical Genetics. 2016; 90:403-412
Schmidt LS, Warren MB, Nickerson ML, et al. Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. American Journal of Human Genetics. 2001; 69(4):876-882
Bonné AC, Bodmer D, Schoenmakers EF, van Ravenswaaij CM, Hoogerbrugge N, van Kessel AG. Chromosome 3 translocations and familial renal cell cancer. Current Molecular Medicine. 2004; 4(8):849-854
Aarnio M, Säily M, Juhola M, et al. Uroepithelial and kidney carcinoma in Lynch syndrome. Familial Cancer. 2012; 11(3):395-401
Schultz KAP, Rednam SP, Kamihara J, et al. PTEN, DICER1, FH, and their associated tumor susceptibility syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clinical Cancer Research. 2017; 23(12):e76-e82
Haven CJ, Wong FK, van Dam EW, van der Juijt R, van Asperen C, Jansen J, et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. The Journal of Clinical Endocrinology and Metabolism. 2000; 85(4):1449-1454
Iwashita H, Okudela K, Matsumura M, et al. Succinate dehydrogenase B-deficient renal cell carcinoma: A case report with novel germline mutation. Pathology International. 2017; 67(11):585-589
Schlegelberger B, Kreipe H, Lehmann U, et al. A child with Li-Fraumeni syndrome: Modes to inactivate the second allele of TP53 in three different malignancies. Pediatric Blood & Cancer. 2015; 62(8):1481-1484
Popova T, Herbert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. American Journal of Human Genetics. 2013; 92:974-980
Stratton KL, Alanee S, Glogowski EA, et al. Outcome of genetic evaluation of kidney cancer patients referred for suspected hereditary cancer syndromes. Urologic Oncology. 2016; 34(5):238.e1-238.e7
Guo J, Tretiakova MS, Troxell ML, et al. Tuberous sclerosis-associated renal cell carcinoma: A clinicopathologic study of 57 separate carcinomas in 18 patients. The American Journal of Surgical Pathology. 2014; 38:1457-1467
Peron A, Vignoli A, La Briola F, et al. Do patients with tuberous sclerosis complex have an increased risk for malignancies? American Journal of Medical Genetics. Part A. 2016; 170(6):1538-1544
Alessandri JL, Cuillier F, Ramful D, et al. Perlman syndrome: Report, prenatal findings and review. American Journal of Medical Genetics - Part A. 2008; 146A(19):2532-2537. DOI: 10.1002/ajmg.a.32391
Levitt NC, Hickson ID. Caretaker tumour suppressor genes that defend genome integrity. Trends in Molecular Medicine. 2002; 8(4):179-186
Shu X, Gu J, Huang M, et al. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome. Carcinogenesis. 2018; 39(6):752-757
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399:271-275
Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015; 347(6217):78-81
Haber DA, Settleman J. Cancer: Drivers and passengers. Nature. 2007; 446:145-146
Knudson AG Jr. Mutation and cancer: Statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America. 1971; 68:820-823
Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 1997; 386:761-763
de Vogel S, Weijenberg MP, Herman JG, et al. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: Indications for distinct pathways and sequence of events. Annals of Oncology. 2009; 20(7):1216-1222
Tovar EA, Graveel CR. MET in human cancer: Germline and somatic mutations. Annals of Translational Medicine. 2017; 5(10):205
Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology. 2010; 28(5):893-901
Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology. 2015; 33(31):3660-3667
Lammens CR, Bleiker EM, Verhoef S, Ausems MG, Majoor-Krakauer D, Sijmons RH, et al. Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromes. Psycho-Oncology. 2011; 20(6):631-638
Aktan-Collan K, Mecklin JP, Järvinen H. Predictive genetic testing for hereditary non-polyposis colorectal cancer: Uptake and long-term satisfaction. International Journal of Cancer. 2000; 89(1):44-50
van Leeuwaarde RS, Saya A, Links TP, Giles RH. Von Hippel-Lindau Syndrome. Initial Posting: May 17, 2000; Last Update: September 6, 2018
Balmaña J, Digiovanni L, Gaddam P, et al. Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. Journal of Clinical Oncology. 2016; 34(34):4071-4078
Richards S, Aziz N, Bale S. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015; 17(5):405-424
Shirts BH, Casadei S, Jacobson AL. Improving performance of multigene panels for genomic analysis of cancer predisposition. Genetics in Medicine. 2016; 18(10):974-981
Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of Clinical Oncology. 2013; 31:181-186
Staehler M, Goebell PJ, Müller L, et al. Rare patients in routine care—Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry. International Journal of Cancer. 2019; 146:1307-1315
Hasumi H, Yao M. Hereditary kidney cancer syndromes: Genetic disorders driven by alterations in metabolism and epigenome regulation. Cancer Science. 2018; 109(3):581-586
Freifeld Y, Ananthakrishnan L, Margulis V. Imaging for screening and surveillance of patients with hereditary forms of renal cell carcinoma. Current Urology Reports. 2018; 19(10):82
PDQ Cancer Information Summaries. PDQ Cancer Genetics Editorial Board. Genetics of Kidney Cancer (Renal Cell Cancer) Health Professional Version. 2019
Maher ER. Hereditary renal cell carcinoma syndromes: Diagnosis, surveillance and management. World Journal of Urology. 2018; 36:1891-1898
Gonorazky HD, Naumenko S, Ramani AK, et al. Expanding the boundaries of RNA sequencing as a diagnostic tool for rare Mendelian disease. American Journal of Human Genetics. 2019; 104(5):1007
Hampel H, Peralman R, et al. Assessment of tumor sequencing as a replacement for lynch syndrome screening and current molecular tests for patients with colorectal cancer. JAMA Oncology. 2018; 4(6):806-813. DOI: 10.1001/jamaoncol.2018.0104
Hasumi H, Furuya M, Tatsuno K, et al. BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Human Molecular Genetics. 2018; 27(15):2712-2724
Park I, Shim YS, Go H, et al. Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures. BMC Urology. 2019; 19(1):51
Hwang JW, Desterke C, Féraud O, et al. iPSC-Derived embryoid bodies as models of c-Met-mutated hereditary papillary renal cell carcinoma. International Journal of Molecular Sciences. 2019; 20(19)
Kankuri M, Pelliniemi TT, Pyrhönen S, et al. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: A phase II study. Cancer. 2001; 92(4):761-767
Schultz CL, Alderfer MA, Lindell RB, et al. The influence of adolescence on parents’ perspectives of testing and discussing inherited cancer predisposition. Journal of Genetic Counseling. 2018. [published online ahead of print, 2018 Jun 16]. DOI: 10.1007/s10897-018-0267-z
Peng YC, Chen YB. Recognizing hereditary renal cancers through the microscope: A pathology update. Surgical Pathology Clinics. 2018; 11(4):725-737